Company intelligence / Profile preview
Altevax
Paris, Île-de-France, Francealtevax.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Altevax is a French clinical-stage biotechnology company pioneering the development of innovative cancer immunotherapies. The company's proprietary platform utilizes synthetic melanin as an adjuvant combined with disease-specific peptides to trigger a highly potent, antigen-specific T-cell immune response. Altevax's lead program, MELITECH (NAVIG-1 vaccine), is currently in a Phase 1/2a clinical trial (NAVIG-1) for the treatment of newly diagnosed glioblastoma, targeting telomerase (TERT) and PTPRZ1. By mimicking a physiological immune response, Altevax aims to deliver highly specific, effective, and well-tolerated treatments for aggressive cancers and infectious diseases.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccinePeptidesBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Assistance Publique - Hôpitaux de Paris
Beyond the preview
Go deeper on Altevax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Altevax.